research use only
Cat.No.S8137
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor ATPase GluR |
|---|---|
| Other TRP Channel Inhibitors | 2-APB (2-Aminoethyl Diphenylborinate) SKF96365 AMG-517 GSK2193874 GSK1016790A HC-030031 EIPA (L593754) HC-067047 SB705498 ML-SI3 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| CHO | Function assay | Inhibition of capsaicin-induced [Ca2+] uptake by Rat Vanilloid receptor 1 (VR1) expressing CHO cells, Ki=0.52μM | 12825950 | |||
| CHO | Function assay | Inhibition of capsaicin-induced calcium uptake by transient receptor potential vanilloid type 1 expressed in CHO cells, IC50=0.42μM | 15634002 | |||
| CHO | Function assay | Antagonist activity towards rat TRPV1 expressed in CHO cells, Ki=0.52μM | 15993063 | |||
| CHO | Function assay | In vitro inhibition of [3H]RTX binding to rat TRPV1 expressed in CHO cells, Ki=1.3μM | 15993063 | |||
| HEK293 | Function assay | Inhibition of 100 nM capsaicin effect on intracellular [Ca2+] concentration in HEK293 cells expressing human TRPV1, IC50=0.0562μM | 16000002 | |||
| CHO | Function assay | Antagonist activity for rat TRPV1 expressed in CHO cells, Ki=0.52μM | 16005215 | |||
| CHO | Function assay | In vitro binding affinity for rat TRPV1 expressed in CHO cells using [3H]-RTX, Ki=1.3μM | 16005215 | |||
| human TRPV1 expressing cells | Function assay | Inhibition of calcium influx evoked by capsaicin in human TRPV1 expressing cells by fluorescence assay, IC50=0.334μM | 16420034 | |||
| CHO | Function assay | Antagonist activity at rat TRPV1 expressed in CHO cells assessed as inhibition of calcium uptake, Ki=0.52μM | 17035013 | |||
| CHO | Function assay | Displacement of [3H]RTX from rat TRPV1 expressed in CHO cells, Ki=1.3μM | 17035013 | |||
| CHO | Function assay | Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by aequorin based assay, IC50=0.039μM | 17489570 | |||
| CHO | Function assay | Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay, IC50=0.053μM | 17489570 | |||
| CHO | Function assay | Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by [45Ca2+] uptake assay, IC50=0.069μM | 17489570 | |||
| CHO | Function assay | Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by aequorin based assay, IC50=0.22μM | 17489570 | |||
| CHO | Function assay | Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by aequorin based assay, IC50=0.32μM | 17489570 | |||
| CHO | Function assay | Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay, IC50=0.887μM | 17489570 | |||
| CHO | Function assay | Antagonist activity at rat TRPV1 receptor expressed in CHO cells assessed as calcium 45 uptake, Ki=0.52μM | 18072720 | |||
| CHO | Function assay | Displacement of [3H]RTX from rat TRPV1 receptor expressed in CHO cells, Ki=1.3μM | 18072720 | |||
| HEK293 | Function assay | Antagonist activity at human TRPV1 expressed in tetracycline-stimulated HEK293 cells assessed as inhibition of capsaicin-induced intracellular calcium levels by fluorimetric assay, EC50=2.51189μM | 20381363 | |||
| HEK293T | Function assay | Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of CAP-induced intracellular Ca2+ influx by fluorescence-based assay, IC50=0.15μM | 24484240 | |||
| HEK293T | Function assay | 10 uM | Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of proton-induced intracellular Ca2+ influx at 10 uM by fluorescence-based assay | 24484240 | ||
| HEK T-REx cells | Function assay | >50 uM | Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of icilin-induced intracellular Ca2+ influx at >50 uM by fluorescence-based assay | 24484240 | ||
| HEK293T | Function assay | 100 uM | Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of proton-induced intracellular Ca2+ influx at 100 uM by fluorescence-based assay | 24484240 | ||
| T-REx HEK cells | Function assay | 3 mins | Antagonist activity against human TRPV1 expressed in T-REx HEK cells assessed as inhibition of capsaicin-induced increase in intracellular Ca2+ accumulation pre-incubated for 3 mins prior to capsaicin stimulation by Fluo-4 AM dye based fluorescence assay, IC50=0.068μM | 25052206 | ||
| T-REx HEK cells | Function assay | 3 mins | Antagonist activity against mouse TRPM8 expressed in T-REx HEK cells assessed as inhibition of cold-induced increase in intracellular Ca2+ accumulation pre-incubated for 3 mins prior to cold stimulation by Fluo-4 AM dye based fluorescence assay | 25052206 | ||
| HeLa | Antiproliferative assay | 24 hrs | Antiproliferative activity against human HeLa cells after 24 hrs by cell titer 96 aqueous non-radioactive cell proliferation assay, IC50=30μM | 30528162 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: Insoluble
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 376.90 | Formula | C19H21ClN2O2S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 138977-28-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CC2=CC(=C(C=C2CN(C1)C(=S)NCCC3=CC=C(C=C3)Cl)O)O | ||
| Targets/IC50/Ki |
TRPV1
Na,K-ATPase
12 μM(EC50)
|
|---|---|
| In vitro |
Capsazepine(CPZ) at a concentration of 94.2 µg/ml (IC50 concentration of this compound) exhibits a statistically significant inhibition of osteoclast growth and proliferation. This compound converts the NKA into Na-ATPase. It inhibits K+-dependent activity but allows Na-ATPase associated with Na+ transport. CPZ has no effect on Na-ATPase measured in the absence of K+. This chemical also inhibits para-nitrophenyl phosphatase activity, albeit with a lower affinity. It strongly reduces the steady-state EP level and the Na+ affinity for phosphorylation decreased 3-fold after CPZ treatment. In summary, this compound blocks an Na+/K+ cycle in the NKA but leaves an Na+ cycle intact, reducing the transport stoichiometry of the pump. This chemical inhibits osteoclast formation and bone resorption in a dose dependent manner in bone marrow-osteoblast co-cultures and RANKL generated osteoclast cultures. It also suppresses RANKL induced IκB and ERK1/2 phosphorylation and causes apoptosis of mature osteoclasts and also inhibits alkaline phosphatase activity and bone nodule formation in calvarial osteoblast cultures. |
| In vivo |
Capsazepine pre-treatment prevents the increase in respiratory system resistance and decreases the increase in tissue damping during endotoxemia. This compound also attenuates lung injury by a reduction in the collapsed area of the lung parenchyma induced by lipopolysaccharide (LPS). |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.